Computer models to improve combination treatments for diffuse large B‑cell lymphoma
Official title: Modeling and analysis of curative combination therapy for Diffuse Large B-Cell Lymphoma
Funded at Univ of North Carolina Chapel Hill · NIH-11260268 · Data updated 2026-11-12
This project builds computer simulations to help design better combination drug regimens for people with diffuse large B‑cell lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $309,991 |
| NIH project number | 5R01CA279968-03 |
| Project ID | NIH-11260268 on NIH RePORTER |
Who could benefit from this research
✓Could help
People diagnosed with diffuse large B‑cell lymphoma, especially those interested in or enrolled in combination therapy clinical trials, are the most relevant group.
✕Less likely to help
Patients with other cancer types or non‑cancer conditions are unlikely to receive direct benefit from this DLBCL‑focused modeling work.
What this research studies
Researchers will create computer simulations that combine data from past clinical trials, drug dosing, and tumor behavior to mimic how DLBCL responds to multi‑drug treatment. The models will include differences between patients and differences inside each tumor, plus drug interactions, schedules, and side‑effect tolerability. They will test the simulations by comparing their predictions to results from earlier trials and use successful models to suggest new combination regimens. The goal is to guide future clinical trials toward more curative and less toxic therapy options for patients.
Why it matters
Potential benefit: If successful, this could help design combination therapies that increase cure rates and reduce harmful side effects for people with DLBCL.
How similar studies have gone: Related modeling approaches have previously predicted outcomes in several solid‑tumor trials and aided drug approvals, but applying these methods to curative DLBCL regimens with intra‑tumor heterogeneity is newer and less tested.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Palmer, Adam Christopher — Univ of North Carolina Chapel Hill
- Study coordinator: Palmer, Adam Christopher
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.